TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 2 Study of DS-8500a in Japanese Subjects With Type 2 Diabetes Mellitus (T2DM)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Patients aged ≥ 20 years at the time of informed consent~* Japanese patients with type 2 diabetes~* Patients who have HbA1c ≥ 7.0% and \< 10.0%~Exclusion Criteria:~* Patients with type 1 diabetes mellitus or with a history of diabetic coma, precoma, or ketoacidosis~* Patients receiving or requiring treatment with insulin~* Patients with a body mass index (BMI) of \< 18.5 kg/m2 or ≥ 35.0 kg/m2~* Patients with clinically evident renal impairment (estimated glomerular filtration rate \[eGFR\] of \< 45 mL/min per 1.73 m2) or clinically significant renal disease~* Patients with fasting plasma glucose ≥ 240 mg/dL

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DS-8500a 25 mg QD (Type: EXPERIMENTAL): DS-8500a 25 mg tablet once daily (QD), orally, for up to 12 weeks, and matching sitagliptin placebo capsule
- DS-8500a 50 mg QD (Type: EXPERIMENTAL): DS-8500a 50 mg QD tablet, orally, once daily for up to 12 weeks, and matching sitagliptin placebo capsule
- DS-8500a 75 mg QD (Type: EXPERIMENTAL): DS-8500a 75 mg QD tablet, orally, once daily for up to 12 weeks, and matching sitagliptin placebo capsule
- placebo (Type: PLACEBO_COMPARATOR): placebo tablet and placebo capsule, orally, once daily for up to 12 weeks to match DS-8500a and sitagliptin, respectively.
- Sitagliptin (Type: ACTIVE_COMPARATOR): capsule, orally, once daily for up to 12 weeks and matching DS-8500 placebo tablet

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Remifentanil And Local Anesthesia Compared With Local Anesthesia For The Insertion Of Central Venous Catheters

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* more than 18 years old~* eligible for CVC insertion~Exclusion Criteria:~* pregnancy~* patients who can't give their consent~* contra-indications to remifentanil infusion

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Remifentanil (Type: EXPERIMENTAL): Patients who undergone a Central Venous Catheter (CVC) insertion under remifentanil infusion
- Placebo (Type: PLACEBO_COMPARATOR): Patients who undergone a Central Venous Catheter (CVC) insertion under placebo infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Vitamin D Supplementation on Muscle Mass and Function

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Physical activity scores in the low to very low category~* Fitness estimations in the below average or lower categories~* body mass index scores \>24.9 indicating overweight or obesity.~Exclusion Criteria:~* Use of tanning booths or other artificial UV light exposure~* High baseline vitamin D and calcium intake~* Plans to visit sunny/warm destinations during the winter months/study period~* History or presence of metabolic disease, type 2 diabetes, eating disorders, gastrointestinal disorders, pregnancy or lactation~* Use of drugs to treat obesity (last 12 weeks)~* Use of over the counter anti-obesity agents (last 12 weeks)~* Recent initiation of an exercise program (last four weeks).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- Vitamin D (Type: EXPERIMENTAL): Participants in this arm consumed a 4000 IU vitamin D supplement daily for 12 weeks while participating in a resistance exercise training program.
- Placebo (Type: PLACEBO_COMPARATOR): Participants in this arm consumed a placebo (microcrystalline cellulose) daily for 12 weeks while participating in a resistance exercise training program.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Morphine Analgesia in Patients With Acute Appendicitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* clinical signs of acute appendicitis~* planned for appendectomy~* supposed to wait for at least 1 hour in the ED before operation~Exclusion Criteria:~* suspicion to perforated appendicitis~* being under the age of 13~* pregnancy (according to history and ß-HCG result)~* opium addiction~* systolic blood pressure of less than 90 mmHG~* known cases of chronic obstructive pulmonary disease (COPD)~* known sensitivity to morphine~* history of sickle cell disease~* self administration of analgesics before enrollment~* refusal to participate

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A CBT-based Mobile Intervention as First Line Treatment for Adolescent Depression During COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Between the ages of 13 and 21~* Self-reported symptoms of depression~* Will be residing in the USA for the duration of the 5-week study~* Under the care of a US-based primary care and/or licensed mental healthcare provider and willing and able to provide the name and contact information of the provider during consent appointment.~* English fluency and literacy of adolescent and consenting legal guardian if under 18~* Access to a smartphone (iPhone 5s or later or running Android 4.4 KitKat or later) and regular internet access~* Willing to provide informed e-consent/assent and have legal guardian willing to provide informed e-consent if under 18.~Exclusion Criteria:~* Self-reported lifetime suicide attempt or active self-harm or active suicidal ideation with intent~* Have a diagnosis by a clinician of bipolar disorder, substance use disorder, or any psychotic disorder including schizophrenia~* Incapable of understanding or completing study procedures and digital intervention as determined by participant, patient/legal guardian, healthcare provider, or clinical research team

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: 21 Years
- Healthy Volunteers: t

Study Arms:
- Limbix Spark (Type: EXPERIMENTAL): A 5 week CBT-based intervention
- Psychoeducation (Type: ACTIVE_COMPARATOR): 5 weeks of psychoeducation about depression. Upon completion, participants will be automatically enrolled into the Limbix Spark CBT-based intervention

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison Between Wound Vacuum Dressing and Standard Closure to Reduce Rates of Surgical Site Infections

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient to undergo pancreaticoduodenectomy for pancreatic tumors at the Johns Hopkins Hospital~* Patient treated with neoadjuvant chemotherapy with or without radiation therapy prior to surgical resection, AND/OR placement of a biliary stent and/or drain for biliary tree decompression~Exclusion Criteria:~* Age 18 years or younger~* Laparoscopic or robotic pancreaticoduodenectomy~* Patient did not undergo either placement of a preoperative biliary stent/drain or neoadjuvant chemotherapy with or without radiation therapy~* All patients who are have known allergies or are sensitive to silver and acrylic adhesives

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Prevena Peel & Place Dressing for wound closure (Type: EXPERIMENTAL): In the participants randomized to this arm the surgical site will be closed using Prevena Peel \& Place Dressing.
- Standard closure of the wound (Type: PLACEBO_COMPARATOR): In the participants randomized to this arm the surgical site will be closed using the standard closure technique.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of Bridging Anticoagulation for Surgery (The BRIDGE Study)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Receiving warfarin therapy for at least 3 months, administered to achieve an international normalized ratio (INR) range of 2.0 to 3.0~* Requiring temporary interruption of warfarin for pre-specified elective procedure or surgery~* Presence of one of the following conditions:~  1. Chronic (permanent or paroxysmal) nonvalvular atrial fibrillation, confirmed by at least one prior electrocardiography recording or pacemaker or acid citrate dextrose (ACD) interrogation~ 2. Chronic (permanent or paroxysmal) valvular atrial fibrillation with evidence of mitral valvular heart disease, confirmed by the same criteria as nonvalvular atrial fibrillation~* Presence of at least one of the following major stroke risk factors:~  1. Older than 75 years of age~ 2. Hypertension~ 3. Diabetes mellitus~ 4. Congestive heart failure or left ventricular dysfunction~ 5. Previous ischemic stroke, systemic embolism, or transient ischemic attack (TIA)~Exclusion Criteria:~* Any mechanical prosthetic heart valve~* Stroke (ischemic or hemorrhagic), systemic embolism, or TIA within the past 12 weeks~* Venous thromboembolism (deep vein thrombosis and/or pulmonary embolism) within past 12 weeks~* Major bleeding within the past 6 weeks~* Severe renal insufficiency, measured through a calculated creatinine clearance of less than 30 mL/min~* Thrombocytopenia~* Life expectancy less than 1 month~* Condition that impairs compliance with trial protocol, such as cognitive impairment, an uncontrolled psychiatric condition, or geographic inaccessibility~* Pregnancy~* Allergy to heparin or history of heparin-induced thrombocytopenia~* Having one of the following surgeries or procedures during warfarin interruption:~  1. Cardiac surgery, such as coronary artery bypass or heart valve replacement~ 2. Neurosurgery that is intracranial or intraspinal, such as tumor resection or aneurysm repair~ 3. High-risk non-surgical procedures, such as brain biopsy~* Other surgical or non-surgical procedure that, at the discretion of the surgeon, precludes administration of therapeutic-dose low molecular weight heparin (LMWH) at any time in the post-procedure period~* More than one surgery planned during the trial period~* Prior participation in this trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- Dalteparin (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trial Comparing Three Strategies of Vaccination Against the Virus of Hepatitis B in HIV Infected Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Age Eligible for Study: 18 years - NA, Genders Eligible for Study: Both~Criteria~Inclusion criteria:~* HIV infection~* T CD4 count cell level above 200 per mm3~* Serology Hepatitis B negative (AgHBs, AbHBs and AbHBc negative)~* unchanged ARV for the last 3 months for patients who are receiving ARV at the screening visit~* Undetectable for the last 6 months with ARV for any patient with T CD4 level below 350 per mm3~* Pregnancy test negative at the screening and inclusion visits~Exclusion Criteria:~* Any injection of the vaccine against Hepatitis B in the medical history~* Acute cytolysis in the last 3 months with transaminases equal or above 5 times the upper normal range for HIV-HCV coinfected patients, or transaminases equal or above 2 times the upper normal for non coinfected patients~* Any vaccine received one month before the inclusion~* History of intolerance to any component of GenHevac-B~* Evolutive opportunistic infection treated the month before the screening visit~* Severe and acute pyretic infection or unexplained fever the week before inclusion~* Evolutive hemopathy or solid-organ cancer~* Prothrombin factor equal or below 50 percent and/or platelets equal or below 50 000 per mm3~* Immunosuppressive treatment or general corticotherapy (equal or above 0,5 mg per kg per day during above 7 days) in the last 6 months before the screening visit~* Previous Immunomodulating treatment (interferon, interleukin-2,etc) or plan in the next 6 months~* Splenectomy~* Decompensated cirrhosis (Child Pugh B or C)~* Kidney deficient function (creatinine clearance below 50 ml per mn)~* Other immunocompromised condition not related to HIV infection (solid-organ transplantation, chemotherapy in the last 6 months)~* Any participation to another clinical trial plan until Week 28

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: ACTIVE_COMPARATOR): GenHevac-B 20 microgramme Intramuscular use at M0, M1, M6
- B (Type: EXPERIMENTAL): GenHevac-B 40 microgramme Intramuscular use at M0, M1, M2, M6
- C (Type: EXPERIMENTAL): GenHevac-B 4 microgramme Intradermal use at M0, M1, M2, M6

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Long Term Post-Marketing Study on the EffIcacy and Safety of Osmotic Release Oral System (OROS) Methylphenidate on the Cognitive Functions of Attention Deficit Hyperactivity Disorder (ADHD) Participants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ADHD children must sign the consent form in person, and their parents or guardian must endorse, in the consent form, participation of the child in the designated research program~* Through personal interaction and assessment questionnaire, examine to determine compliance of DSM-IV ADHD diagnostic criteria~* According to the judgment of researchers, the ADHD children should have normal intelligence. Normal intelligence is defined as no obvious evidence of mental retardation in general (specific learning disabilities will not be considered mental retardation in general), formal IQ test to be conducted and 85 marks or above ought to be scored~* ADHD children should not have been subjected to psychotropic drug treatment within 6 months. Those ADHD children on whom methylphenidate immediate-release tablets treatment is effective (with maximum daily dosage of 60 mg), may be admitted~* Normal children with IQ greater than or equal to 85~Exclusion Criteria:~* Unable to fully comply with the cognitive function test in the laboratory~* Known to be allergic to methylphenidate~* Consumption of psychoactive drugs currently or in the past 30 days, including use of monoamine oxidase inhibitors, clonidine, other alpha 2 adrenergic receptor agonists, tricyclic antidepressants, theophylline, bishydroxycoumarin etc~* History of alcohol, drugs or substances abuse~* Have medical history of type I or II bipolar affective disorder, anxiety disorder, schizophrenia or pervasive developmental disorder

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: 12 Years
- Healthy Volunteers: t

Study Arms:
- OROS-MPH Group (Type: EXPERIMENTAL): Participants with ADHD will receive OROS -MPH starting at initial dosage of 18 milligram per day (mg/d) which can be increased to 36 mg/d up to a maximum dosage of 54 mg/d according to the therapeutic effect and tolerance or maintained at 36 mg or re-adjusted to 18 mg due to intolerance.
- Normal Group (Type: ACTIVE_COMPARATOR): Participants did not receive any study drug in this group. Participants were assessed for changes in the cognitive functions and the efficacy was compared with ADHD children.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation and Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Candidates for routine, uncomplicated cataract surgery~In Investigator's opinion, potential postoperative Snellen Distance VA by pinhole method of at least 20/200 in study eye.~Exclusion Criteria:~* Known hypersensitivity/contraindication to study product(s) or components.~* History of glaucoma, intraocular pressure (IOP) \>21 mmHg at the screening or randomization visits, or being treated for glaucoma in either eye.~* Diagnosis of: ongoing ocular infection; severe/serious ocular condition that in judgment of Investigator could confound study assessments or limit compliance; severe/serious systemic disease or uncontrolled medical condition that in judgment of Investigator could confound study assessments or limit compliance; or have been exposed to an investigational drug within the 30 days prior to screening or 18 days following surgery.~* In the opinion of Investigator or study coordinator, be unwilling or unable to comply with study protocol or unable to successfully instill eye drops.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- KPI-121 1.0% Ophthalmic Suspension (Type: ACTIVE_COMPARATOR): dosed BID
- Vehicle of KPI-121 Ophthalmic Suspension (Type: PLACEBO_COMPARATOR): dosed BID

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Secondary Prevention of Cardiovascular Disease in the Elderly Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients diagnosed with a type 1 myocardial infarction within the previous 6 months.~2. Subjects must be ≥65 years old, presenting with at least one of the following additional conditions:~   * Documented diabetes mellitus or previous treatment with oral hypoglycemic drugs or insulin.~  * Mild to moderate renal dysfunction: creatinine clearance 60-30 mL/min/1.73 m2.~  * Prior myocardial infarction: defined as an AMI occurring before the index event documented in a medical report.~  * Prior coronary revascularization: coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI).~  * Prior stroke: history of a documented stroke, defined as an acute episode of focal cerebral, spinal, or retinal dysfunction caused by infarction of central nervous system tissue, not resulting in death.~  * Age ≥ 75 years.~3. Signing informed consent.~Exclusion Criteria:~1. Unable to sign informed consent.~2. Contraindications to any of the components of the polypill.~3. Living in a nursing home.~4. Mental illness limiting the capacity of self-care.~5. Participating in another clinical trial.~6. Severe congestive heart failure (NYHA III-IV).~7. Severe renal disease (Creatinine Clearance (CrCl) \<30ml/min/1.73 m2).~8. Need for oral anticoagulation at the time of randomization or planned in the future months.~9. Any condition limiting life expectancy \<2 years, including but not limited to active malignancy.~10. Significant arrhythmias (including unresolved ventricular arrhythmias or atrial fibrillation).~11. Scheduled coronary revascularization (patients can be randomized after final revascularization is completed within the prespecified timeframe).~12. Do not agree to the filing, forwarding and use of his/ her pseudonymised data.

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment Prevention for Secondary CV (Type: ACTIVE_COMPARATOR): Patients allocated to the usual care arm will receive standard of care therapies for secondary prevention according to the ESC guidelines. Drugs and doses will be left at the discretion of the treating physicians..
- Cardiovascular Polypill (Type: EXPERIMENTAL): Patients allocated to the experimental arm will receive a cardiovascular polypill containing aspirin 100 mg, atorvastatin (40 or 20 mg) and ramipril (2.5, 5 or 10 mg) taken orally once a day.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Dalfampridine in Patients With Hereditary Spastic Paraplegia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Hereditary Spastic Paraplegia at least 1 year ago~Exclusion Criteria:~* Having another neurological disorder~* An orthopedic deformity in the lower extremity~* Having a serious cognitive impairment

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Medication (Type: EXPERIMENTAL): Dalfampridine plus physiotherapy
- No Medication (Type: PLACEBO_COMPARATOR): Placebo plus physiotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete